Research
Hormonal
Thiazolidinediones (specifically Pioglitazone) reduce the incidence of type 2 diabetes in individuals with impaired glucose tolerance, but their use is limited by adverse effects such as weight gain, fluid retention, and increased fracture risk.
Pioglitazone can prevent diabetes, but it often causes weight gain and other side effects. It is usually not the first choice; Metformin or GLP-1 medications are typically preferred unless Pioglitazone is specifically indicated for your case.
GoodQualifiesMEDIUM confidence
The annual rate of T2DM was 7.6% in placebo-treated vs. 2.1% in pioglitazone treated subjects (HR 0.28, p<0.0001)... Undesirable effects of TZDs include fluid retention, increased risk of heart failure, weight gain and loss of bone density increasing fracture risk.
Why this rating
Based on RCTs (PIPOD, ACT NOW) showing significant risk reduction, but with noted safety issues.
Source
Pharmacological approaches to the prevention of type 2 diabetes mellitus
Priyanka Majety et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1118848
narrative_reviewCited 86×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin (850mg twice daily) reduces the incidence of type 2 diabetes by 31% in adults with prediabetes compared to placebo, with effects persisting for up to 22 years.Good
- GLP-1 receptor agonists (specifically Liraglutide 3.0mg and Semaglutide 2.4mg) significantly reduce the incidence of type 2 diabetes in obese individuals with prediabetes, often outperforming placebo and sometimes matching or exceeding lifestyle interventions.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →